Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances

Gwilym J Webb; Gideon M Hirschfield

doi:10.1038/nrgastro.2016.201

Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances

Gwilym J Webb
, Gideon M Hirschfield

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

526 Downloads (Pure)

Abstract

In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and immunological mechanistic insights.

Original language	English
Pages (from-to)	76-78
Number of pages	3
Journal	Nature Reviews. Gastroenterology & Hepatology
Volume	14
Issue number	2
Early online date	11 Jan 2017
DOIs	https://doi.org/10.1038/nrgastro.2016.201
Publication status	Published - Feb 2017

Keywords

obeticholic acid
Primary biliary cholangitis
cholangiocytes
Cholestatic liver disease
biliary

Access to Document

10.1038/nrgastro.2016.201

40122_1_art_file_344410_2hpx5zHighDefPBCAccepted author manuscript, 108 KBLicence: None: All rights reserved

The roles and control of CD4+ effector and regulatory T-cells in biliary autoimmunity
Webb, G. (Principal Investigator)
Medical Research Council
8/09/14 → 7/09/17
Project: Research Councils

Cite this

@article{d4e93f7623c541fdba0524cae66c8661,

title = "Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances",

abstract = "In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and immunological mechanistic insights.",

keywords = "obeticholic acid, Primary biliary cholangitis, cholangiocytes, Cholestatic liver disease, biliary",

author = "Webb, \{Gwilym J\} and Hirschfield, \{Gideon M\}",

year = "2017",

month = feb,

doi = "10.1038/nrgastro.2016.201",

language = "English",

volume = "14",

pages = "76--78",

journal = "Nature Reviews. Gastroenterology \& Hepatology",

issn = "1759-5045",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Primary biliary cholangitis in 2016

T2 - High-definition PBC: biology, models and therapeutic advances

AU - Webb, Gwilym J

AU - Hirschfield, Gideon M

PY - 2017/2

Y1 - 2017/2

N2 - In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and immunological mechanistic insights.

AB - In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and immunological mechanistic insights.

KW - obeticholic acid

KW - Primary biliary cholangitis

KW - cholangiocytes

KW - Cholestatic liver disease

KW - biliary

UR - https://www.scopus.com/pages/publications/85009200790

U2 - 10.1038/nrgastro.2016.201

DO - 10.1038/nrgastro.2016.201

M3 - Article

C2 - 28074075

SN - 1759-5045

VL - 14

SP - 76

EP - 78

JO - Nature Reviews. Gastroenterology & Hepatology

JF - Nature Reviews. Gastroenterology & Hepatology

IS - 2

ER -

Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances

Abstract

Keywords

Access to Document

Fingerprint

Projects

The roles and control of CD4+ effector and regulatory T-cells in biliary autoimmunity

Cite this